EBR Systems, a medtech capitalised at $454 million on the ASX, was out rattling the tin on Wednesday morning to commercialise its wireless cardiac pacemaker that received approval from the US Food and Drug Administration earlier this month.
Brian Oakley can once again walk up the stairs at the MCG after being fitted with the WiSE device.
Loading...
Sarah Thompson has co-edited Street Talk since 2009, specialising in private equity, investment banking, M&A and equity capital markets stories. Prior to that, she spent 10 years in London as a markets and M&A reporter at Bloomberg and Dow Jones. Email Sarah at sarah.thompson@afr.com
Emma Rapaport is a co-editor of the Street Talk column. Prior to that, she was a markets reporter at The Australian Financial Review. Connect with Emma on Twitter. Email Emma at emma.rapaport@afr.com
